DermBiont

Skin microbiome therapeutics platform to treat and prevent skin diseases.

Launch date

2017

Employees

Market cap

Enterprise valuation

AUD216m (Public information from Oct 2023)

Cambridge Massachusetts (HQ)

Date	Investors	Amount	Round
-	Start Capital Joyance Partners Alchimia Investments	N/A	-
Aug 2018	N/A	N/A	Series A
Jun 2019	Toba Capital Viking Global Investors Zola Global	$8.0m	Series A
Feb 2020	N/A	$2.9m	Debt
Oct 2020	N/A	$7.2m	Early VC
Feb 2021	N/A	$6.6m	Debt
Dec 2021	Toba Capital Olive Tree Capital Viking Global Investors Civilization Ventures Nan Fung Life Sciences	$28.0m	Series A
Sep 2022*	N/A	$2.5m	Debt
Mar 2023*	N/A	$4.7m	Debt
Oct 2023*	Olive Tree Capital Viking Global Investors Civilization Ventures Double Point Ventures	$27.1m Valuation: $140m	Series B
Oct 2023*	N/A	$8.1m	Convertible
Total Funding		AUD121m

Tech stackLearn more about the technologies and tools that this company uses.

ACQUISITION by DermBiont Dec 2021

Recent News about DermBiont